Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immuno

Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immunologic Endpoint In PREVENT-19 Trial

WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported data from the phase 3 PREVENT-19 trial and Study 307. PREVENT-19 data in both adults aged 18 and older and adolescents aged 12 through 17 showed

Related Keywords

Washington , United States , Gregory Glenn , More Such Health News , Novavax Inc , Novavax , Prototype , Ov2373 , Chieves , Enspecified , Immunologic , Ndpoint , Prevent , Trial ,

© 2025 Vimarsana